Medical treatment for advanced gastroesophageal adenocarcinoma

Current Opinion in Gastroenterology

Volumn 23, Issue 6, 2007, Pages 631-635

  Cen, Putao ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Advanced gastroesophageal cancers; Biologic therapy; Phase III trials; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTHRACYCLINE; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOCHROME P450 2A6; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; TEGAFUR;

ASIAN; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MUCOSAL DISEASE; NEUTROPENIA; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; STOMACH CANCER;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DRUG COMBINATIONS; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 34848846289     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282f0a933     Document Type: Review

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
4. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97:142-146.
5. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261-267.
6. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20:1996-2004.
7. Cunningham DR, Starling S, Iveson N, et al. NCRI Upper GI Study Group. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial [abstract]. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 24 (Suppl 18):LBA4017.
8. Kang YK, Shin WK, Chen DB, et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results [abstract]. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 24 (Suppl 18):LBA4018.
9. Al-Batran SH, Probst J, Hofheinz S, et al. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)[abstract]. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 24 (Suppl 18):LBA4016.
10. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21:54-59.
11. Lutz MW, Wagener H, Vanhoefer DJ, et al. European Organisation for Research and Treatment of Cancer Gastrointestinal Group; Arbeitsgemeinschaft Internistische Onkologie. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007; 25:2580-2585.
12. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24:4991-4997. This provided level one evidence that docetaxel contributes to overall survival of patients with advanced gastroesophageal cancer
13. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group. J Clin Oncol 2007; 25:3210-3216.
14. Tebbutt NS, Strickland T, Van Hazel A, et al. ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago- gastric cancer, final results of an AGITG trial [abstract]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl 18):4528.
15. Ajani JP, Ho A, Tetzlaff L, et al. Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer [abstract]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl 18):4612.
16. Dank MZ, Barone J, Valvere C, et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients [abstract]. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (Suppl 16):4003.
17. Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23:6957-6965.
18. Hoff PM, Saad ED, Ajani JA, et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003; 9:134-142.
19. van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18:2772-2779.
20. Boku NY, Shirao S, Doi K, et al. Gastrointestinal Oncology Study Group/ Japan Clinical Oncology Group. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912) [abstract]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl 18):LBA4513.
21. Narahara HK, Hara W, Takagane T, et al. TS-1 Advanced Gastric Cancer (AGC) Clinical Trial Group. Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer [abstract]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25(Suppl 18):4514.
22. Chin KI, Imamura H, Kobayashi H, et al. Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP-002) [abstract]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl 18):LBA4525.
23. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24:5201-5206.
24. Enzinger PF, Meyerhardt P, Stuart J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer [abstract]. In: Abstracts of the Gastrointestinal Cancers Symposium 2006; 26-28 January 2006; San Francisco. Alexandria: American Society of Clinical Oncology; 2006. Abstract 68.
25. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18:510-517.
26. Lordick FL, Hegewisch-Becker F, Folprecht S, et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group [abstract]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl 18):4526.
27. Stein AAB, Arnold Se, Peinert D, et al. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. In: Abstracts of the Gastrointestinal Cancers Symposium 2007; 19-21 January 2007; Orlando. Alexandria: American Society of Clinical Oncology; 2006. Abstract 47.
28. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24:4922-4927.
29. Adelstein JR, Carroll LA, Rice MA, Mekhail TW. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer [abstract]. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (Suppl 16):4054.
30. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24:1612-1619.
31. Tew W, Shah M, Schwartz G, et al. Phase II trial of erlotonib for second-line treatment in advanced esophageal cancer [abstract]. In: Abstracts of the Gastrointestinal Cancers Symposium 2005; 27-29 January 2005; Hollywood. Alexandria: American Society of Clinical Oncology; 2005. Abstract 5.
32. Rojas Llimpe FDF, Ceccarelli F, Pinto C, et al. Prognostic significance of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study) [abstract]. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (Suppl 18):4604.
33. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007; 25:517-525.
34. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage nonsmall-cell lung cancer. N Engl J Med 2006; 355:570-580.